 Entera Bio Ltd. ENTX, a leader in the development of orally delivered large molecule therapeutics, announced it will report interim three-month top-line biomarker data for the first 50 of the patients enrolled in the Phase 2 osteoporosis clinical trial of EB613 and financial and business results for the quarter ended March 31, 2020, on May 21, 2020, before the U.S. financial markets open. Enteras management will host a conference call on Thursday, May 21, 2020 at 8:30 a.m. EDT to present the data and discuss the results for the quarter. A question-and-answer session will follow Enteras remarks. 